| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Minocycline-d6 sulfate is an isotope-labeled internal standard and does not have a specific pharmacological target. The unlabeled parent compound, Minocycline, targets bacterial ribosomes to inhibit protein synthesis, acting as a bacteriostatic antibiotic. Minocycline also inhibits HIF-1α, a transcription factor that regulates cellular responses to hypoxia. Additionally, Minocycline has anti-inflammatory, neuroprotective, and antidepressant properties through various mechanisms.
|
|---|---|
| ln Vitro |
As a deuterated internal standard, Minocycline-d6 sulfate itself does not exhibit biological activity. Its utility lies in its use as an analytical standard for the quantification of Minocycline in biological and pharmaceutical samples. The deuterium labeling provides a mass shift that enables accurate quantification by mass spectrometry without chromatographic interference from the unlabeled compound.
|
| ln Vivo |
Minocycline-d6 sulfate is not a therapeutic compound and is not evaluated for in vivo activity. Its primary application is in analytical chemistry and pharmaceutical development, where it is used as an internal standard for the quantification of Minocycline in biological samples. The deuterated form is not administered to animals for pharmacological studies.
|
| Enzyme Assay |
Non-cell-based protocols for Minocycline-d6 sulfate involve LC-MS/MS or GC-MS analysis. A typical workflow includes sample preparation (protein precipitation, liquid-liquid extraction, or solid-phase extraction), chromatographic separation on a suitable column, and MS/MS detection in MRM mode using the characteristic mass transitions of the deuterated compound. The deuterated internal standard is added to samples prior to extraction to correct for matrix effects and extraction recovery.
|
| Cell Assay |
Cellular assays are not applicable to Minocycline-d6 sulfate as it is an analytical standard. The unlabeled parent compound Minocycline is evaluated in cell-based assays for its antibiotic, anti-inflammatory, neuroprotective, and anticancer activities. Typical assays include bacterial susceptibility testing, cytokine production assays, and cell viability assays.
|
| Animal Protocol |
In vivo animal studies with Minocycline-d6 sulfate are not conducted as it is an analytical standard. The unlabeled parent compound Minocycline is administered to animals for pharmacological and toxicological studies, including models of infection, inflammation, neurodegeneration, and cancer.
|
| ADME/Pharmacokinetics |
As an isotope-labeled internal standard, Minocycline-d6 sulfate has no pharmacokinetic properties of its own. The unlabeled parent compound Minocycline is orally effective, can cross the blood-brain barrier, and has a half-life of approximately 11–17 hours in humans. It is primarily excreted in urine and feces.
|
| Toxicity/Toxicokinetics |
As a research-use isotope-labeled compound, Minocycline-d6 sulfate is not intended for human therapeutic use, and toxicological data are not applicable. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Minocycline-d6 sulfate is a deuterium-labeled form of Minocycline, a semi-synthetic tetracycline antibiotic and HIF-1α inhibitor that is orally effective and can cross the blood-brain barrier. Minocycline has bacteriostatic, anti-cancer, anti-inflammatory, neuroprotective, and antidepressant properties. Minocycline-d6 sulfate is used as an internal standard for the quantification of Minocycline in biological samples by mass spectrometry.
|
| Molecular Formula |
C23H23D6N3O11S
|
|---|---|
| Molecular Weight |
561.59
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7807 mL | 8.9033 mL | 17.8066 mL | |
| 5 mM | 0.3561 mL | 1.7807 mL | 3.5613 mL | |
| 10 mM | 0.1781 mL | 0.8903 mL | 1.7807 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
